Zepbound vs Wegovy: A two horse race
Release Date:
Last week, the FDA approved Eli Lilly's obesity drug Zepbound, creating an anticipated intense competition between it and Novo Nordisk's Wegovy. BioSpace's Greg Slabodkin, Tyler Patchen and Lori Ellis discuss the weight loss race and the future of this drug class.
Plus, a quick recap on Valneva, the FDA's first Chikungunya vaccine approval.
Zepbound vs Wegovy: A two horse race